Institutional investors adjust Moderna holdings as Vanguard raises stake
Vanguard increased its Moderna stake by 1.0% in the fourth quarter to 41.6 million shares worth $1.23 billion. Other institutional investors also adjusted positions, while 75.33% of the stock is held by institutions and hedge funds.
Vanguard Group Inc. increased its position in Moderna, Inc. by 1.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,584,782 shares of the company's stock after buying an additional 399,487 shares during the period. Vanguard Group Inc. owned 10.64% of Moderna worth $1,226,335,000 at the end of the most recent quarter.
Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Moderna by 19.2% during the fourth quarter. The fund owned 139,654 shares of the company's stock after acquiring an additional 22,485 shares during the quarter, and its holdings were worth $4,118,000 as of its most recent SEC filing.
Thrivent Financial for Lutherans reduced its position in shares of Moderna by 85.7% in the third quarter. The fund owned 13,341 shares of the company's stock after selling 79,658 shares during the period, and its holdings were worth $345,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also made changes to their positions in Moderna. M&T Bank Corp raised its holdings in shares of Moderna by 1,313.8% during the fourth quarter to 258,698 shares worth $7,629,000 after acquiring an additional 240,400 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its position by 8.1% during the fourth quarter to 86,358 shares valued at $2,698,000 after acquiring an additional 6,459 shares during the last quarter. Bayforest Capital Ltd grew its holdings by 44.9% in the fourth quarter to 21,969 shares valued at $648,000 after purchasing an additional 6,812 shares in the last quarter, while Mirae Asset Global Investments Co. Ltd. increased its position by 18.7% to 77,183 shares worth $2,276,000 after purchasing an additional 12,144 shares during the last quarter.
Additional filings cited changes in other periods. AQR Capital Management LLC acquired a new position in shares of Moderna during the first quarter worth approximately $415,000. NewEdge Advisors LLC grew its holdings in Moderna by 732.7% in the first quarter to 11,575 shares valued at $328,000 after buying an additional 10,185 shares in the last quarter, while Focus Partners Wealth increased its position by 58.7% during the first quarter to 23,547 shares worth $668,000 after buying an additional 8,706 shares during the period. American Century Companies Inc. lifted its holdings in shares of Moderna by 5.2% during the second quarter to 48,859 shares worth $1,348,000 after buying an additional 2,410 shares in the last quarter.
Vanguard Group Inc. also was cited in a separate filing as boosting its position by 3.2% in the second quarter to 41,708,705 shares valued at $1,150,743,000 after acquiring an additional 1,312,192 shares during the period. Geode Capital Management LLC raised its stake in Moderna by 19.1% in the second quarter to 8,877,280 shares worth $244,458,000 after purchasing an additional 1,420,690 shares in the last quarter. Theleme Partners LLP boosted its holdings by 8.6% in the second quarter to 7,868,810 shares valued at $217,100,000 after purchasing an additional 626,420 shares during the period, Invesco Ltd. grew its position by 20.7% to 7,101,032 shares worth $195,917,000 after purchasing an additional 1,217,408 shares in the last quarter, and Norges Bank acquired a new position during the second quarter worth approximately $94,910,000.
Across the filings, 75.33% of the stock is owned by institutional investors and hedge funds. Corporate insiders own 10.80% of the company's stock.
Moderna last posted quarterly earnings results on February 13. The company reported ($2.11) earnings per share for the quarter, topping the consensus estimate of ($2.79) by $0.68, and revenue of $678.00 million compared to analyst estimates of $611.14 million. The firm's revenue for the quarter was down 33.2% on a year-over-year basis, while Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%.
In related news, the president sold 160,009 shares of the stock on February 23 at an average price of $48.84, for a total transaction of $7,814,839.56. Following the sale, the president owned 1,457,427 shares in the company, valued at approximately $71,180,734.68. This trade represents a 9.89% decrease in the position.